ERBB4 and neoplasm: In addition, a significantly higher number of tumours expressing HER-3 (P = 0.037), or co-expressing EGFR/HER-3 (P = 0.035), or HER-3/HER-4 (P = 0.026) were found in tumours <pT4 stage in this study (Table 4).